Abcam, ab258410, Human EPHA4 (Eph receptor A4/SEK) knockout HeLa cell lysate

Size: 1Kit
EPHA4 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-EPHA4, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Eph receptor A4 also known as SEK is a type of ephrin receptor that plays a significant role in cellular communication. It belongs to the Eph protein family and it is classified as a receptor tyrosine kinase. EphA4 has an approximate molecular mass of 110 kDa. It is mainly expressed in the nervous system although it can also be found in other tissues including the vascular and skeletal systems. This receptor has an important function in mediating signal transduction upon binding with their ephrin ligands.
Biological function summary
EphA4 plays a critical role in developmental processes particularly in the development of the nervous system and vascular patterning. The receptor engages in bidirectional signaling meaning that signals are transmitted not only into the receptor-expressing cells but also into the ephrin-expressing ones. EphA4 is part of complexes that can include multiple receptor and ephrin molecules which allows for the modulation of cell adhesion and migration. These processes are essential for forming tissue boundaries and axon guidance.
Pathways
EphA4 signaling is involved in two significant pathways: the Eph/ephrin signaling pathway and the cytoskeletal remodeling pathway. In the Eph/ephrin signaling pathway EphA4 interacts with various ephrin ligands leading to changes in cellular architecture and behavior. The cytoskeletal remodeling pathway involves interactions with proteins such as Rho and Ras which coordinate cytoskeletal changes necessary for cell movement and positioning. These pathways are integral to processes like axon guidance and cell migration underpinning EphA4’s role in development.
EphA4 has been implicated in conditions such as amyotrophic lateral sclerosis (ALS) and cancer metastasis. In the context of ALS EphA4's interaction with proteins like RhoA affects axonal repair and neuron survival contributing to the disease's progression. Regarding cancer EphA4 influences tumor growth and spread with its signaling pathways impacting cellular invasion and angiogenesis. Understanding these aspects of EphA4 activity assists in developing therapeutic strategies for these disorders.